3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
10
Gemcitabine
8
Cyclophosphamide
7
Filgrastim
5
Docetaxel
5
Carboplatin
5
Trastuzumab
4
Surveys and Questionnaires
4
Nivolumab
4
Doxorubicin
4
Cisplatin
4
poly ICLC
3
pazopanib
3
atezolizumab
3
aldesleukin
3
Taxes
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Ipilimumab
3
Injections
3
Drug Therapy
3
Cetuximab
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Clinical Trials, Phase II as Topic
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled